Department of Medicine.
Cardiometabolic Program, National Institute of Health Research, University College London Hospitals/University College London Biomedical Research Centre, and.
Blood. 2018 Feb 22;131(8):845-854. doi: 10.1182/blood-2017-10-804096. Epub 2017 Dec 18.
Disseminated intravascular coagulation (DIC) is a condition characterized by systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, thereby contributing to organ dysfunction. At the same time, ongoing consumption of platelets and coagulation proteins results in thrombocytopenia and low concentrations of clotting factors, which may cause profuse hemorrhagic complications. DIC is always secondary to an underlying condition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamities. A reliable diagnosis of DIC can be made through simple scoring algorithms based on readily available routine hemostatic parameters. The cornerstone of supportive treatment of this coagulopathy is management of the underlying condition. Additionally, administration of heparin may be useful, and restoration of physiological anticoagulants has been suggested, but has not been proven successful in improving clinically relevant outcomes so far. In patients with major bleeding or at risk for hemorrhagic complications, administration of platelet concentrates, plasma, or coagulation factor concentrates should be considered.
弥散性血管内凝血(DIC)是一种以全身凝血系统激活为特征的疾病,可能导致小血管和中等大小血管的血栓性阻塞,从而导致器官功能障碍。同时,血小板和凝血蛋白的持续消耗会导致血小板减少和凝血因子浓度降低,这可能导致大量出血并发症。DIC 总是继发于某种基础疾病,如严重感染、实体瘤或血液系统恶性肿瘤、创伤或产科灾难。通过基于易于获得的常规止血参数的简单评分算法可以可靠地诊断 DIC。这种凝血异常的支持治疗的基石是基础疾病的治疗。此外,肝素的使用可能是有用的,并且已经提出恢复生理抗凝剂,但迄今为止尚未证明在改善临床相关结局方面是成功的。对于有大出血风险或有出血并发症风险的患者,应考虑输注血小板浓缩物、血浆或凝血因子浓缩物。